Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis

Company Overview

Eagle Pharmaceuticals, Inc. was a specialty pharmaceutical company focused on developing and commercializing injectable and intranasal medicines, with an emphasis on products intended to improve existing therapies through differentiated formulations, dosing approaches, or delivery technologies. The company primarily served hospital, oncology, emergency medicine, and critical-care markets.

Eagle’s marketed products included Ryanodex, an injectable formulation of dantrolene sodium used to treat malignant hyperthermia; Belrapzo, a formulation of bendamustine hydrochloride used in certain blood cancers; and Pemfexy, a ready-to-dilute formulation of pemetrexed used in the treatment of certain lung cancers and mesothelioma. Its commercial activities were concentrated mainly in the United States, with selected products and rights supported through external partners in international markets.

Founded in 2007, Eagle was led for much of its history by founder and Chief Executive Officer Scott Tarriff. In 2024, Pharmacosmos A/S completed its acquisition of Eagle Pharmaceuticals, and Eagle became part of the Pharmacosmos Group. As a result, Eagle is no longer an independently traded company on the Nasdaq exchange, although its products and pharmaceutical operations continue under its parent organization.

Key Stats

• Today's Range: $0.95 to $0.95
• 50-Day Range: $0.16 to $3.94
• 52-Week Range: $0.00 to $3.94
• Volume: N/A
• Average Volume: 7,410 shs
• Market Capitalization: $12.34 million
• P/E Ratio: 0.81
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Eagle Pharmaceuticals Stock Analysis - MarketRank™

Eagle Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Eagle Pharmaceuticals.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Eagle Pharmaceuticals is 0.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.12.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eagle Pharmaceuticals is 0.81, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.76.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.37% of the float of Eagle Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eagle Pharmaceuticals has a short interest ratio ("days to cover") of 12.74, which indicates bearish sentiment.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eagle Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eagle Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.10

News Sentiment

Eagle Pharmaceuticals has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Eagle Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for EGRX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Eagle Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

85.36% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/09/2021
• Today: 11/02/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:EGRX
• Previous Symbol: NASDAQ:EGRX
• CIK: 827871
• Web: www.eagleus.com
• Phone: (201) 326-5300
• Fax: N/A
• Employees: 100
• Year Founded: 2007

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.81
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $257.55 million
• Price / Sales: 0.05
• Cash Flow: $2.38 per share
• Price / Cash Flow: 0.40
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 12,987,000
• Free Float: 9,234,000
• Market Cap: $12.34 million
• Optionable: No Data
• Beta: 0.83